Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages

  Zhaoxia, Liang ^a   Ying, Wu ^a   Danqing, Chen ^a  

^a Zhejiang University School of Medicine   (China)

Author keywords

Gestational diabetes mellitus (GDM); Oral glucose tolerance test (OGTT); Visfatin

Indexed keywords

CHOLESTEROL; GLUCOSE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY; PREGNANCY DIABETES MELLITUS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES, GESTATIONAL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREGNANCY;

EID: 84862220422     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.02.020     Document Type: Article

References (18)

1. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
2. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:295-299.
3. Gok D.E., Yazici M., Uckaya G., Bolu S.E., Basaran Y., Ozgurtas T., et al. The role of visfatin in the pathogenesis of gestational diabetes mellitus. J Endocrinol Invest 2011, 34:3-7.
4. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Plasma visfatin concentration and fat depot specific mRNA express in humans. Diabetes 2005, 54:2911-2916.
5. Morgan S.A., Bringolf J.B., Seidel E.R. Visfatin expression is elevated in normal human pregnancy. Peptides 2008, 29:1382-1389.
6. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
7. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110:605-609.
8. Mastorakos G., Valsamakis G., Papatheodorou D.C., Barlas I., Margeli A., Boutsiadis A., et al. The role of dipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem 2007, 53:1477-1483.
9. Lewandowski K.C., Stojanovic N., Press M., Tuck S.M., Szosland K., Bienkiewicz M., et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007, 50:1033-1037.
10. Chan T.F., Chen Y.L., Lee C.H., Chou F.H., Wu L.C., Jong S.B., et al. Decreased plasma visfatin concentration in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006, 13:364-367.
11. Akturk M., Altinova A.E., Mert I., Buyukkagnici U., Sargin A., Arslan M., et al. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 2008, 31:610-613.
12. Moschen A.R., Gerner R.R., Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 2010, 16:1913-1920.
13. Mazaki-Tovi S., Vaisbuch E., Romero R., Kusanovic J.P., Chaiworapongsa T., Kim S.K., et al. Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis. Am J Reprod Immunol 2010, 63:252-262.
14. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006, 49:1909-1914.
15. Bala M., Martin J., Kopp A., Hanses F., Buechler C., Schäffler A. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1). J Clin Endocrinol Metab 2011, 96:2493-2501.
16. Esteghamati A., Alamdari A., Zandieh A., Elahi S., Khalilzadeh O., Nakhjavani M., et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2011, 91:154-158.
17. Li L., Yang G., Li Q., Tang Y., Yang M., Yang H., et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006, 114:544-548.
18. Haider D.G., Handisurya A., Storka A., Vojtassakova E., Luger A., Pacini G., et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. Diabetes Care 2007, 30:1889-1891.